foxo4-dri senolytic peptide human trials nct FOXO4-DRI: Trial Status, Cancer Research & Data FOX04-DRI foxo4-dri senolytic 2024 FOXO4-DRI: Human

CagriSema is a new weight loss medication that combines two medicines: cagrilintide and semaglutide

BPC-157 is a synthetic peptide of 15 amino acids derived from a naturally occurring gastric protein

Therapeutic injections do just that

When recovery slows down, training volume, progressive overload, and performance can all suffer

Book your appointment for the month of June and receive our special pricing

For spinal structures with naturally limited blood supply (particularly the intervertebral discs, which are largely avascular), this enhanced circulation to surrounding tissues can make a meaningful difference in healing capacity